Click to see our news releases about special projects and other announcements.Read More
Journalists: We are at your service. Please contact us with your request.Connect
CRI iAtlas is a comprehensive web-based resource that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment. The iAtlas team released immuno-oncology modules that allow investigators to access and work with genomics data from trials of treatment with immune-checkpoint inhibitors.
Members of ISB’s Heath Lab and their collaborators have developed a way to sensitively detect and analyze neoantigen-specific T-cell populations from tumors and blood. This promising development may have implications for creating targeted, individual-specific cancer vaccines.
ISB President Dr. Jim Heath and ISB Co-founder Dr. Lee Hood are prominently featured in a new podcast created by Ozy, the popular news website. The podcast is called “The Future of X.” In the series’ first episode, Heath and Hood discuss cancer immunotherapy, personalized health care, and more.
The Andy Hill Cancer Research Endowment (CARE) announced $750,000 in grant funding for Dr. Jim Heath’s work on proactive cancer immunotherapies for initial and recurrent disease. This is the first stage of a planned longer program led by Jim and ISB, and involving Swedish Cancer Institute, Earl A. Chiles Research Institute in Portland, and UW Medicine.
Three organizations on the forefront of cancer immunotherapy, systems biology and bioinformatics announced the release of the Cancer Research Institute iAtlas, a comprehensive web-based tool that allows oncologists and researchers to study and analyze interactions between tumors and the immune microenvironment.